共 50 条
Sleep Problems in Patients With Psoriatic Arthritis: A Systematic Literature Review and Metaanalysis
被引:2
|作者:
Grant, Carly
[1
]
Woodbury, Michael
[1
]
Skougaard, Marie
[2
]
Boldsen, Jens K.
Ogdie, Alexis
[3
]
Klerman, Elizabeth B.
[4
,5
]
Merola, Joseph F.
[6
]
Perez-Chada, Lourdes M.
[1
]
机构:
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, 221 Longwood Ave, Boston, MA 02115 USA
[2] Aarhus Univ Hosp, Dept Clin Immunol, Aarhus, Denmark
[3] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Dept Med,Div Rheumatol, Philadelphia, PA USA
[4] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA
[5] Harvard Med Sch, Div Sleep Med, Boston, MA USA
[6] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol & Med, Div Rheumatol, Boston, MA USA
基金:
美国国家卫生研究院;
关键词:
psoriasis;
psoriatic arthritis;
quality of life;
sleep;
sleep disorders;
QUALITY-OF-LIFE;
HEALTH;
DETERMINANTS;
ASSOCIATION;
PREVALENCE;
INDEX;
D O I:
10.3899/jrheum.2022-1169
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective. The aim of this systematic review and metaanalysis is to summarize evidence regarding the relationship between psoriatic arthritis (PsA) and sleep problems. Methods. We identified 36 eligible studies-26 cross-sectional, 7 cohort, and 3 interventional studies-in PubMed and Embase. Results. The prevalence of self-reported sleep problems in patients with PsA ranged from 30% to 85%. A metaanalysis of 6 studies that used the Pittsburgh Sleep Quality Index revealed a prevalence of poor sleep quality for patients with PsA of 72.9% (95% CI 63-81.8; I2 = 78%), which was statistically higher than in healthy controls (26.9%, 95% CI 11.7-45.4; I2 = 81%) but not significantly different than in patients with psoriasis (59.8%, 95% CI 46.9-72.1; I2 = 51%). Sleep disturbance was ranked in the top 4 health-related quality of life domains affected by PsA. One study suggested a bidirectional relationship between PsA and obstructive sleep apnea. Predictors of sleep problems included anxiety, pain, erythrocyte sedimentation rate, depression, fatigue, physical function, and tender or swollen joint count. Tumor necrosis factor inhibitors, guselkumab, and filgotinib (a Janus kinase inhibitor) were associated with improved sleep outcomes. Conclusion. Poor sleep quality is prevalent in patients with PsA. Objective sleep measures (ie, actigraphy and polysomnography) have not been used in PsA studies, and evidence on the validity ofpatient-reported sleep measures in PsA is lacking. Future studies should validate self-reported sleep measures in PsA, explore how sleep quality relates to PsA disease activity and symptoms using both objective and subjective sleep measures, assess the efficacy of strategies to manage sleep problems, and assess the effects of such management on symptoms and disease signs in patients with PsA.
引用
收藏
页码:1594 / 1609
页数:16
相关论文